Cancers & treatments·Regimen libraryFirst line

Carboplatin + paclitaxel + bevacizumab, then bevacizumab maintenance

Checked 2026-09-09

Stage III-IV ovarian cancer, especially with residual disease or ascites

Also called Carboplatin-paclitaxel-bevacizumab.

One cycle

every 21 days × 6 · about 18 weeks in total

21-day cycle × 6 with chemotherapy; bevacizumab to 15 months (GOG-218) or 12 months (ICON7) (about 18 weeks)Intravenous

Components

Drug	Dose	Route	Days
Carboplatin Cytotoxic chemotherapy (platinum)	AUC 6	IV	D1
Paclitaxel Cytotoxic chemotherapy (taxane)	175 mg/m²	IV	D1
Bevacizumab Monoclonal antibody (anti-VEGF)	15 mg/kg (7.5 mg/kg in ICON7), from cycle 2	IV	D1

Cycles

6 with chemotherapy; bevacizumab to 15 months (GOG-218) or 12 months (ICON7)

21-day cycle

Emetogenicity

High (>90%)

G-CSF

Not routine

Notes

PAOLA-1: add olaparib 300 mg twice daily for 2 years in HRD-positive disease.

Used in

Ovarian cancer

Trials

GOG-0218 & ICON7 (bevacizumab)PAOLA-1 / ENGOT-ov25

Products

CarboplatinPaclitaxel / nab-paclitaxelBevacizumab

Source

GOG-0218, NEJM 2011

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.